NASDAQ: BIOL | Healthcare / Medical Devices & Instruments / USA |
1.11 | -0.0400 | -3.48% | Vol 86.12K | 1Y Perf 17.35% |
Nov 29th, 2023 15:59 DELAYED |
BID | 1.10 | ASK | 1.14 | ||
Open | 1.20 | Previous Close | 1.15 | ||
Pre-Market | - | After-Market | 1.11 | ||
- - | - -% |
Target Price | 14.00 | Analyst Rating | Strong Buy 1.00 | |
Potential % | 1.16K | Finscreener Ranking | ★★★+ 51.38 | |
Insiders Trans % 3/6/12 mo. | -/-/33 | Value Ranking | ★★ 45.52 | |
Insiders Value % 3/6/12 mo. | -/-/85 | Growth Ranking | + 32.12 | |
Insiders Shares Cnt. % 3/6/12 mo. | -/-/81 | Income Ranking | — - | |
Price Range Ratio 52W % | 0.04 | Earnings Rating | Buy | |
Market Cap | 2.55M | Earnings Date | 9th Nov 2023 | |
Alpha | -0.08 | Standard Deviation | 0.34 | |
Beta | 1.34 |
Today's Price Range 1.101.20 | 52W Range 1.07104.00 | 5 Year PE Ratio Range -1.10-1.20 |
Summary:
Sell
Technical Indicators: | Neutral |
Moving Averages: | Strong Sell |
Performance | |||
---|---|---|---|
1 Week | -9.02% | ||
1 Month | -34.71% | ||
3 Months | -74.77% | ||
6 Months | 1 221.43% | ||
1 Year | 17.35% | ||
3 Years | 268.89% | ||
5 Years | -3.48% | ||
10 Years | -87.53% |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -92.63 | |||
ROE last 12 Months | -122.83 | |||
ROA (5Y Avg) | -24.19 | |||
ROA last 12 Months | -52.51 | |||
ROC (5Y Avg) | -66.32 | |||
ROC last 12 Months | -62.31 | |||
Return on invested Capital Q | -24.42 | |||
Return on invested Capital Y | -11.38 | |||
Assets Turnover | 0.80 | |||
Receivables Turnover | 8.10 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-0.20 | ||||
0.37 | ||||
0.16 | ||||
- | ||||
-0.20 | ||||
-3.72 | ||||
0.47 | ||||
1.94 | ||||
10.06M | ||||
Forward PE | -12.39 | |||
PEG | -0.18 |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
1.10 | ||||
2.50 | ||||
0.51 | ||||
1.07 | ||||
-12.40 | ||||
Leverage Ratio | 2.60 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
36.80 | ||||
-47.40 | ||||
-46.30 | ||||
-49.30 | ||||
-54.56 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
34.41M | ||||
4.46 | ||||
-5.14 | ||||
-8.50 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q01 2024 | - | -8.93 | - |
Q01 2023 | - | -0.18 | - |
Q03 2022 | - | -1.10 | - |
Q02 2022 | - | -0.91 | - |
Q01 2022 | - | -0.81 | - |
Q04 2021 | -0.75 | -0.75 | 0.00 |
Q03 2021 | -0.75 | -0.50 | 33.33 |
Q02 2021 | -1.00 | -0.50 | 50.00 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
9/2019 QR | -0.21 | 0.00 | - |
3/2022 QR | -0.03 | 70.00 | Positive |
12/2022 FY | -0.10 | - | - |
12/2022 FY | -0.10 | 0.00 | - |
Next Report Date | - |
Estimated EPS Next Report | - |
Estimates Count | - |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 86.12K |
Shares Outstanding | 2.30K |
Shares Float | 2.30M |
Trades Count | 518 |
Dollar Volume | 97.18K |
Avg. Volume | 273.89K |
Avg. Weekly Volume | 58.96K |
Avg. Monthly Volume | 456.09K |
Avg. Quarterly Volume | 306.62K |
Biolase Inc. (NASDAQ: BIOL) stock closed at 1.11 per share at the end of the most recent trading day (a -3.48% change compared to the prior day closing price) with a volume of 86.12K shares and market capitalization of 2.55M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 157 people. Biolase Inc. CEO is John R. Beaver.
The one-year performance of Biolase Inc. stock is 17.35%, while year-to-date (YTD) performance is 70.77%. BIOL stock has a five-year performance of -3.48%. Its 52-week range is between 1.07 and 104, which gives BIOL stock a 52-week price range ratio of 0.04%
Biolase Inc. currently has a PE ratio of -0.20, a price-to-book (PB) ratio of 0.37, a price-to-sale (PS) ratio of 0.16, a price to cashflow ratio of -, a PEG ratio of -0.18, a ROA of -52.51%, a ROC of -62.31% and a ROE of -122.83%. The company’s profit margin is -54.56%, its EBITDA margin is -46.30%, and its revenue ttm is $34.41 Million , which makes it $4.46 revenue per share.
Of the last four earnings reports from Biolase Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Biolase Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Biolase Inc. is Strong Buy (1), with a target price of $14, which is +1 161.26% compared to the current price. The earnings rating for Biolase Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Biolase Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Biolase Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 34.66, ATR14 : 0.13, CCI20 : -75.91, Chaikin Money Flow : -0.64, MACD : -0.18, Money Flow Index : 3.99, ROC : -22.03, RSI : 26.49, STOCH (14,3) : 10.39, STOCH RSI : 0.00, UO : 40.51, Williams %R : -89.61), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Biolase Inc. in the last 12-months were: Jonathan T. Lord (Sold 3 537 shares of value $2 653 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Strong Buy | Strong Buy | Strong Buy |
Biolase Inc is a US-based medical device company. It develops, manufactures, markets and sells laser systems in dentistry and medicine. The company also markets, sells and distributes dental imaging equipment, including cone beam digital x-rays and CAD/CAM intraoral scanners. It offers two categories of laser system products i.e. Waterlase (all-tissue) systems and Diode (soft-tissue) systems which allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The majority of the company's revenue comes from the United States.
CEO: John R. Beaver
Telephone: +1 949 361-1200
Address: 4 Cromwell, Irvine 92618, CA, US
Number of employees: 157
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Copyright © 2023. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer.
General partner of Finscreener is SLOVAKODATA, a.s.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.